Adam Lezack - 21 May 2026 Form 4 Insider Report for Beta Bionics, Inc. (BBNX)

Reporting relationship: Director
Issuer ticker: BBNX
Reported as of: 21 May 2026
Net transaction value: -$21,138
SEC form: 4
Accepted by SEC: 26 May 2026, 18:00:27 UTC
Prior SEC filing: 14 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Stephen Feider, Attorney-in-Fact

Key filing fact

Adam Lezack filed Form 4 for Beta Bionics, Inc. (BBNX) on 26 May 2026.

Key facts

This page summarizes Adam Lezack's Form 4 filing for Beta Bionics, Inc. (BBNX).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 26 May 2026, 18:00.

Change

Previous filing in this sequence was filed on 14 Jan 2026.
Current net transaction value: -$21,138.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002048466 Primary reporting owner

Lezack Adam

Relationship: Director
Address: C/O BETA BIONICS, INC., 11 HUGHES, IRVINE
Signature: /s/ Stephen Feider, Attorney-in-Fact
Signature date: 26 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBNX transaction

Common Stock

Sale

Transaction value: $9,950
Shares: -1,000
Change %: -8%
Price: $9.95
Shares after: 11,432
Date: 21 May 2026
Ownership: Direct
Footnotes: F1

BBNX transaction

Common Stock

Award

Transaction value
Shares: +16,965
Change %: +148%
Price: $0.000000^*
Shares after: 28,397
Date: 21 May 2026
Ownership: Direct
Footnotes: F2

BBNX transaction

Comon Stock

Sale

Transaction value: $11,188
Shares: -998
Change %: -3.5%
Price: $11.21
Shares after: 27,399
Date: 22 May 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025.

Footnote F2

Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.